Tesamorelin: FDA-Approved GH Protocol

Category: Protocols Type: Protocol Read Time: 16 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/tesamorelin-protocol

Educational content only. Not medical advice. Consult a licensed healthcare provider before starting any protocol.

Overview

Tesamorelin (research code TH9507, brand name Egrifta) is a stabilized analog of growth hormone-releasing hormone (GHRH). Its defining structural feature is a trans-3-hexenoyl modification at the N-terminus, which protects the molecule from rapid degradation by dipeptidyl peptidase-4 (DPP-4) and extends its functional half-life relative to native GHRH.

Tesamorelin was developed by Theratechnologies and received FDA approval in 2010 for the reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy. It remains the only FDA-approved GHRH analog on the U.S. market and the only peptide specifically indicated for visceral fat reduction.

Outside its labeled indication, Tesamorelin is widely used off-label by endocrinologists, anti-aging clinics, and longevity-focused practitioners for adults seeking visceral fat reduction, modest IGF-1 elevation, and sleep architecture improvements. Compounded versions are also dispensed through specialty pharmacies, though regulatory scrutiny in this area continues to evolve.

Key Properties:

• 44-amino-acid GHRH analog
• Trans-3-hexenoyl modified for protease resistance
• FDA-approved (Egrifta SV / Egrifta WR)
• Preferential effect on visceral (vs subcutaneous) fat
• Preserves endogenous pulsatile GH release

Mechanism of Action

Tesamorelin binds to GHRH receptors on the anterior pituitary, stimulating the synthesis and pulsatile release of endogenous growth hormone. Because it works upstream of the pituitary, Tesamorelin generally preserves the natural feedback loop governed by somatostatin — a meaningful safety advantage over exogenous recombinant human growth hormone (rHGH).

Primary pathways:

1. GHRH receptor agonism — Activates cAMP signaling in pituitary somatotrophs, driving GH gene transcription and secretion.
2. Prolonged half-life — The hexenoyl modification slows enzymatic cleavage, extending circulating activity compared to unmodified GHRH or sermorelin.
3. IGF-1 elevation — Pulsed GH release downstream raises serum IGF-1 modestly into mid-to-upper physiologic range.
4. Visceral lipolysis — GH preferentially mobilizes free fatty acids from visceral adipose depots, which are more responsive to lipolytic GH signaling than subcutaneous fat.
5. Sleep architecture — Endogenous GH pulses are tied to slow-wave sleep; users frequently report deeper sleep on protocol.

Compared with sermorelin (a shorter, unstabilized GHRH 1-29 fragment), Tesamorelin produces a longer, more pronounced GH response per dose.

Dosing Protocols

Dosing varies sharply between the on-label clinical protocol and off-label use. The table below summarizes commonly referenced ranges.

Timing considerations:

• Evening dosing aligns with the natural nocturnal GH pulse and supports sleep-onset GH release.
• Take on an empty stomach when possible — elevated blood glucose and free fatty acids blunt GHRH-driven GH secretion.
• Rotate abdominal injection sites to minimize lipoatrophy/lipohypertrophy.

Titration:

Many practitioners start at 1 mg nightly for 2–4 weeks, monitor tolerance (glucose, injection-site reactions), then escalate to the full 2 mg dose if needed.

Tesamorelin vs Alternatives

Tesamorelin sits in a crowded GH-axis category. The comparison below highlights how it stacks against commonly used alternatives.

Practical takeaways:

• vs Sermorelin: Tesamorelin is more potent and produces a more sustained GH pulse per injection, but is far more expensive.
• vs CJC-1295 w/DAC: DAC offers a flatter, longer GH elevation with weekly dosing convenience; Tesamorelin preserves more pulsatility, which some clinicians prefer physiologically.
• vs rHGH: rHGH bypasses the pituitary entirely, producing larger IGF-1 spikes — and a substantially higher risk profile for insulin resistance, edema, and (theoretically) malignancy. Tesamorelin is gentler but cannot match rHGH magnitude.

Expected Outcomes

Clinical trials in HIV-associated lipodystrophy (Falutz et al., Stanley et al.) established the foundational outcome data for Tesamorelin. Results in metabolically healthy off-label users are generally more modest but directionally similar.

Documented outcomes (26-week clinical data):

• Visceral adipose tissue (VAT) reduction: ~8–15% from baseline
• IGF-1 elevation: Mid- to upper-physiologic range (typically +50–100 ng/mL)
• Triglyceride reduction: Modest improvement reported
• Subcutaneous fat: Minimal change — Tesamorelin is not a general fat-loss agent
• Sleep quality: Subjective improvement in deep sleep / recovery
• Body composition: Slight lean mass preservation; not a bulk-building protocol

Realistic timeline:

• Weeks 1–4: Sleep changes, mild injection-site reactions
• Weeks 4–12: Measurable IGF-1 elevation, subjective recovery improvements
• Weeks 12–26: Visceral fat reduction on imaging (CT/MRI gold standard, DEXA acceptable)
• Post-26 weeks: Plateau; continued use studied up to 52+ weeks in HIV cohorts

Discontinuation generally leads to rebound of visceral fat within months. Tesamorelin manages, but does not permanently resolve, central adiposity.

Side Effects & Safety

Tesamorelin has a well-characterized safety profile from its FDA registration trials.

Common adverse effects:

• Injection site reactions — erythema, pruritus, hematoma (most common)
• Arthralgia — joint pain or stiffness, often transient
• Peripheral edema — mild fluid retention
• Myalgia — muscle aches
• Paresthesia — tingling/numbness, especially in extremities

Metabolic considerations:

• Hyperglycemia / insulin resistance — GH antagonizes insulin; monitor fasting glucose and HbA1c
• IGF-1 elevation above range — uncommon at labeled dose but possible
• Carpal tunnel-like symptoms — secondary to fluid retention

Contraindications:

• Active malignancy (theoretical proliferation risk via IGF-1)
• Hypothalamic-pituitary axis disruption (pituitary tumor, recent surgery, radiation)
• Pregnancy and breastfeeding
• Hypersensitivity to mannitol (excipient in Egrifta)
• Severe diabetic retinopathy

Discontinue and re-evaluate if persistent hyperglycemia, new edema, or unexplained joint symptoms develop.

Who Qualifies for Prescription

FDA-labeled indication:

Adults with HIV-associated lipodystrophy and excess abdominal fat. This is the only on-label population covered by Egrifta SV / Egrifta WR.

Off-label criteria some endocrinologists use:

• Adult-onset growth hormone deficiency (confirmed via stim testing)
• Refractory visceral adiposity in metabolic syndrome
• Age-related GH decline with documented low IGF-1
• Post-bariatric or post-weight-loss visceral fat redistribution

Off-label prescribing is at clinician discretion and varies by state and practice. Many longevity and anti-aging clinics in NYC will evaluate candidates with bloodwork, body composition imaging, and a medical history review.

Compounded alternatives:

Compounding pharmacies have historically dispensed Tesamorelin, but the FDA's 2023 guidance has narrowed which peptides can be compounded under 503A. Compounded Tesamorelin is more accessible price-wise than brand Egrifta but exists in a shifting regulatory environment — verify your source's standing carefully.

Stacking

Tesamorelin combines well with select peptides — and combines poorly with others.

Common, well-tolerated stacks:

Tesamorelin + Ipamorelin (or other GHRP) The classic GHRH + GHRP synergy. Tesamorelin amplifies the pituitary's GH-release machinery; ipamorelin (a selective ghrelin mimetic) triggers release. The combination produces a larger GH pulse than either alone, without the cortisol/prolactin elevation seen with older GHRPs.

• Tesamorelin: 1–2 mg nightly
• Ipamorelin: 200–300 mcg nightly, same injection window

Tesamorelin + BPC-157 For users layering joint or tendon support onto a body composition protocol. No known mechanistic conflict.

Avoid:

Tesamorelin + rHGH (somatropin) Mechanistic redundancy with stacked risk — both elevate GH/IGF-1 directly. Stacking compounds insulin resistance and edema risk without added benefit. If rHGH is clinically indicated, Tesamorelin is generally discontinued.

Tesamorelin + high-dose MK-677 long-term Both elevate IGF-1 by different mechanisms; together they can drive IGF-1 above physiologic range and worsen insulin resistance.

Cycling

Clinical trials studied Tesamorelin in continuous use over 26-week and 52-week courses. Real-world off-label protocols often follow similar arcs.

Common cycling approaches:

• Standard course: 6 months continuous, reassess with imaging and bloodwork
• Extended course: 12 months for established responders with stable labs
• 5/2 maintenance: 5 days on, 2 off — preserves receptor sensitivity, reduces cost
• Pulse cycling: 12 weeks on, 4 weeks off — favored by users tracking IGF-1 tightly

Discontinuation reality:

Visceral fat reduction is not durable after stopping. Studies show measurable VAT rebound within ~6 months of discontinuation in most subjects. Plan for either maintenance dosing or a parallel lifestyle program (resistance training, sleep, nutrition) to hold gains.

Bloodwork to Monitor

Tesamorelin is GH-axis-active and has metabolic implications — bloodwork is non-negotiable for responsible use.

Baseline (before starting):

• IGF-1 — primary efficacy and safety marker
• Fasting glucose
• HbA1c
• Comprehensive metabolic panel (CMP) — includes liver enzymes, electrolytes
• Fasting lipid panel
• Body composition — DEXA or CT for VAT baseline (ideal)

Follow-up cadence:

• Week 6–8: IGF-1, fasting glucose, HbA1c
• Month 3: Repeat above + CMP
• Month 6: Full panel + repeat imaging if available
• Annually thereafter if on long-term protocol

Red flag values:

• IGF-1 above age-adjusted reference range
• Rising HbA1c (>5.7% trend)
• New elevation in liver enzymes
• Persistent hyperglycemia

Frequently Asked Questions

Q: Will insurance cover Egrifta? A: For the FDA-labeled HIV-lipodystrophy indication, many insurers cover it with prior authorization. Off-label use is rarely covered, and out-of-pocket brand pricing can exceed $4,000–$5,000/month.

Q: Is there a generic Tesamorelin? A: No FDA-approved generic exists. Compounded Tesamorelin is available through 503A pharmacies but is not a "generic" in the regulatory sense — it is a compounded preparation and quality varies by source.

Q: How does Tesamorelin cost compare to HGH? A: Brand Tesamorelin (Egrifta) is expensive but generally less than long-term prescription rHGH. Compounded Tesamorelin can run $300–$700/month depending on dose and pharmacy. rHGH typically runs $1,000–$3,000+/month at therapeutic doses.

Q: What happens if I stop Tesamorelin? A: Visceral fat tends to return within several months. IGF-1 returns to baseline within weeks. No withdrawal syndrome is documented — Tesamorelin works by stimulating endogenous GH, so the axis is not suppressed.

Q: Is Tesamorelin banned by WADA? A: Yes. Tesamorelin, like all GHRH analogs and GH secretagogues, is on the World Anti-Doping Agency Prohibited List at all times (S2 class). Competitive athletes should not use it.

Q: Can women use Tesamorelin? A: Yes — the original Egrifta trials included both sexes. Dosing is generally the same. Pregnancy and breastfeeding are contraindications.

Q: Will Tesamorelin help me lose subcutaneous fat or build muscle? A: Not meaningfully. It is targeted at visceral (intra-abdominal) fat. Subcutaneous fat changes are minimal, and lean mass gains are modest at best. It is not a body-recomposition agent in the way bodybuilding marketing often suggests.

Q: Can I take Tesamorelin if I have diabetes? A: Caution is warranted. Tesamorelin elevates GH, which is counter-regulatory to insulin. Patients with type 2 diabetes or prediabetes can sometimes use it under close glucose monitoring, but it is not a first-line option and requires endocrinology oversight.

Related Content

• CJC-1295 Protocol
• Ipamorelin Protocol
• MK-677 Protocol
• GH Peptide Stacking Guide
• Bloodwork Checklist
• FDA Status Guide

Disclaimer: This content is for educational purposes only and is not medical advice. Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy; off-label use is at clinician discretion. Compounded versions exist in a shifting regulatory landscape. Always consult a licensed healthcare provider before starting any peptide protocol, and never use without baseline and follow-up bloodwork.

Source: https://peptides.nyc/learn/tesamorelin-protocol